CASE DISCUSSION
Diabetes Care: Insulin Management Techniques
Presented India by Dr. Pradeep Kumar KarumanchiViews
17,154
Credit Points
Learning Hours
CPD Points
CME Points
Courses Completed
Case Description
There are various types of insulin, including rapid-acting, short-acting, intermediate-acting, and long-acting, each with different onset and duration of action. Basal-Bolus Regimen technique involves using both basal (long-acting) and bolus (rapid-acting) insulin to mimic the body's natural...
Case Summary
- Diabetes is a prevalent metabolic disease in India, characterized by the body's inability to produce sufficient insulin or effectively metabolize glucose. It exists primarily in two main types: Type 1, often genetic and diagnosed in childhood, requiring insulin dependence; and Type 2, linked to lifestyle and diet, which may or may not require insulin. Gestational diabetes occurs during pregnancy, and pre-diabetes is an often neglected yet crucial stage.
Speaker Profile
Dr. Pradeep Kumar Karumanchi
Consultant Radiation Oncologist, Yashoda Hospitals, HyderabadDr. Pradeep Kumar Karumanchi is one of the best Radiation Oncologists in Hyderabad with expertise in treating all types of cancers. He has been trained in High Precision Radiotherapy Techniques like Cyberknife, Tomotherapy, SRS, SBRT, VMAT, IGRT, IMRT, TBI and HDR Brachytherapy. He has been trained at prestigious Institutes in India and abroad. He also received specialty training in Urologic Oncology and GI Oncology from world renowned Memorial Sloan-Kettering Cancer Center(MSKCC), USA. He received training in Thoracic Oncology from Univ. of Michigan, USA and Precision Oncology from Univ. de Geneve, Switzerland. He is actively involved in clinical research and has scientific publications in International journals. He believes in the ‘Quality-of-LIfe’ concept and treats patients with special consideration in improving their quality of life. He has special interest in Radiomics and Radio-genomics with Active Precision Oncology Research in the imaging space and the usage of artificial intelligence in prognosticating and predicting the outcomes and side-effects of cancer.
Disclosures
Assimilate requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships for anyone with the ability to control the content of this educational activity have been reviewed and mitigated. Others involved in the planning of this activity have no relevant financial relationships.